Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 736 to 750 of 1688 results for carers

  1. Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]

    Awaiting development [GID-TA11494] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393]

    Awaiting development [GID-TA11486] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Cefepime–enmetazobactam for treating hospital-acquired pneumonia, including ventilator-associated pneumonia TS ID 12035

      Status ...

    Technology appraisal guidance
    Topic selection

  4. Inebilizumab for treating AQP4-IgG seropositive neuromyelitis optica spectrum disorders ID6430

    Awaiting development [GID-TA11530] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322]

    Awaiting development [GID-TA11360] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252]

    Awaiting development [GID-TA11284] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Sumatriptan–naproxen for treating migraine-related moderate to severe headache [TS ID 12055]

      Status ...

    Technology appraisal guidance
    Topic selection

  8. Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6301]

    Awaiting development [GID-TA11338] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Virtual Wards for COPD exacerbations

    Awaiting development [GID-MT608] Expected publication date: TBC

    Medical technologies guidance
    Awaiting development

  10. Tiragolumab with atezolizumab for treating locally advanced unresectable stage 3 non-small-cell lung cancer after at least 2 cycles of platinum-based chemoradiation [ID6250]

    Awaiting development [GID-TA11278] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Dementia: care planning (IND142)

    This indicator covers the percentage of patients diagnosed with dementia whose care plan has been reviewed in a face-to-face review in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM107

    General practice indicators suitable for use in QOF
    Last updated
    4 November 2020

  12. Targeted Muscle Reinnervation for refractory pain after limb amputation

    In development [GID-IPG10369] Expected publication date: 20 June 2025

    Interventional procedures guidance
    In development

  13. Transcatheter aortic valve implantation for native aortic valve regurgitation

    In development [GID-IPG10357] Expected publication date: 11 June 2025

    Interventional procedures guidance
    In development

  14. Laparoscopic insertion of an inactive implant for gastro-oesophageal reflux disease

    In development [GID-IPG10345] Expected publication date: 17 April 2025

    Interventional procedures guidance
    In development

  15. Quality standards: process guide (PMG43)

    This guide describes the process NICE uses to develop NICE quality standards